Production (Stage)
Atai Life Sciences N.V.
ATAI
$2.32
$0.114.98%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 31,200.00% | -112.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 31,200.00% | -112.50% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -185,560.00% | -112.50% | |||
| SG&A Expenses | -12.72% | 11.48% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -29.02% | 29.59% | |||
| Operating Income | 34.34% | -29.84% | |||
| Income Before Tax | 33.67% | -49.91% | |||
| Income Tax Expenses | 117.83% | -303.37% | |||
| Earnings from Continuing Operations | 32.13% | -48.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 3.03% | 32.00% | |||
| Net Income | 32.16% | -48.21% | |||
| EBIT | 34.34% | -29.84% | |||
| EBITDA | 34.57% | -29.32% | |||
| EPS Basic | 38.16% | -48.08% | |||
| Normalized Basic EPS | 6.80% | -9.77% | |||
| EPS Diluted | 38.16% | -48.08% | |||
| Normalized Diluted EPS | 6.80% | -9.77% | |||
| Average Basic Shares Outstanding | 9.68% | 0.06% | |||
| Average Diluted Shares Outstanding | 9.68% | 0.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||